Terms ending in 2029
Every in-force patent on Genmab A/S's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,155,816 | Recombinant Monovalent Antibodies and Methods for Production Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,906,991 | Bispecific Antibodies and Methods for Production Thereof In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,752,695 | STABLE IgG4 ANTIBODIES In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,580,506 | Potency assays for antibody drug substance binding to an fc receptor In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,040,050 | Combination Treatment of CD38-Expressing Tumors In force · High confidence | Genmab A/S | In force | High confidence | |
| US 10,000,570 | Antibody Variants Having Modifications in the Constant Region In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,492,565 | Human Antibody Drug Conjugates Against Tissue Factor In force · High confidence | Genmab A/S | In force | High confidence | |
| US 9,714,297 | Human Antibodies Against Tissue Factor and Methods of Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.